Pyxis Oncology (PYXS) Total Liabilities (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Total Liabilities of $38.1 million for Q4 2025, up 4.62% year-over-year from $36.4 million in Q4 2024, and up 3.49% quarter-over-quarter from $36.8 million in Q3 2025.
Pyxis Oncology (PYXS) Total Liabilities (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Total Liabilities for 6 consecutive years, with $38.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 4.62% year-over-year to $38.1 million; the TTM figure through Dec 2025 stood at $38.1 million (up 4.62% YoY), while the FY2025 annual figure was $38.1 million, up 4.62% from the prior year.
- Total Liabilities advanced to $38.1 million in Q4 2025 per PYXS's latest filing, from $36.8 million in the prior quarter.
- Across five years, Total Liabilities topped out at $50.6 million in Q4 2022 and bottomed at $16.9 million in Q3 2021.
- Historically, Total Liabilities has averaged $34.7 million across 5 years, with a median of $35.8 million in 2024.
- Annual changes were most pronounced in 2021 — Total Liabilities soared 385.42% — and 2024, when it decreased 24.14%.
- Pyxis Oncology's Total Liabilities stood at $18.7 million in 2021, then soared by 170.23% to $50.6 million in 2022, then slipped by 5.01% to $48.0 million in 2023, then dropped by 24.14% to $36.4 million in 2024, then rose by 4.62% to $38.1 million in 2025.
- Business Quant data shows PYXS's Total Liabilities at $38.1 million in Q4 2025, $36.8 million in Q3 2025, and $35.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - | 43.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.48 Mn |
| Dec 31, 2025 | 38.11 Mn |
| Sep 30, 2025 | 36.83 Mn |
| Jun 30, 2025 | 35.57 Mn |
| Mar 31, 2025 | 32.76 Mn |
| Dec 31, 2024 | 36.43 Mn |
| Sep 30, 2024 | 41.63 Mn |
| Jun 30, 2024 | 38.60 Mn |
| Mar 31, 2024 | 36.06 Mn |
| Dec 31, 2023 | 48.02 Mn |
| Sep 30, 2023 | 48.75 Mn |
| Jun 30, 2023 | 29.96 Mn |
| Mar 31, 2023 | 30.64 Mn |
| Dec 31, 2022 | 50.56 Mn |
| Sep 30, 2022 | 35.15 Mn |
| Jun 30, 2022 | 30.60 Mn |
| Mar 31, 2022 | 19.19 Mn |
| Dec 31, 2021 | 18.71 Mn |
| Sep 30, 2021 | 16.90 Mn |
| Dec 31, 2020 | 3.85 Mn |